A new targeted cancer medicine, T-DM1, has shown the potential to shrink tumors in women suffering from metastatic breast cancer, after all 7 popular drugs, including Herceptin, failed.
After extensive study of the effects of drug, which fuses together "Herceptin with a potent chemotherapy drug", it has been revealed that it helps shrink the tumors by using a "Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target".
According to Ian Krop, MD, of the Dana-Farber Cancer Institute in Boston, tumors shrank in about a-third of the women who were on T-DM1, and in another 12% of the women, the tumors stopped growing and progressing for a minimum of 6 months.
"This is the first study looking at women who have failed so many other treatments. But we think these results are as good as we've ever seen is such a refractory [sick] population", said Dr. Krop.
All the women who were considered to study the effects of the medicine had suffered from breast tumors for an average of 3 years, and had cancer that had either metastasized or spread to other parts of the body.
Details of the study and its findings were presented at the San Antonio Breast Cancer Symposium.